



## Recent patents in multiple sclerosis research

Patent #	Subject	Assignee	Author	Priority application date	Publication date
WO 200117535	A method for treating numerous human diseases, for example, human immunodeficiency virus, herpes, multiple sclerosis, and diseases characterized by neoplasia, with a therapeutically effective amount of a porcine liver extract.	Vigen Laboratories (Wilmette, IL)	Frank P, Lawyer CH, Philip WG	9/3/1999	3/15/2001
WO 200115736	A conjugate exhibiting interferon- $\beta$ activity comprising a nonpolypeptide group covalently attached to an interferon- $\beta$ polypeptide; useful for treating multiple sclerosis.	Maxygen ApS (Copenhagen, Denmark)	Andersen KV, Bornaes C, Pedersen AH, Rasmussen PB, Schambye HT	8/27/1999	3/8/2001
WO 200114881	An assay kit containing a combination of affinity ligands able to detect sialocplxes, which are markers of multiple sclerosis and pro-MS immune response; useful for diagnosis and monitoring.	Biocrystal Ltd. (Westerville, OH)	Barbera-Guillem E, Nelson MB	8/22/2000	3/1/2001
WO 200112658	New B7-3 polypeptides useful for modulating inducible co-stimulator protein and for treating ulcers, Crohn's disease, multiple sclerosis, diabetes mellitus, infections, and allergic diseases.	Isis Innovations (Oxford, UK)	Davis S	8/11/1999	2/22/2001
WO 200112622	Use of new and known amine compounds for stimulating neuronal activity for treating Alzheimer's and Parkinson's disease, neuralgias, and multiple sclerosis.	Schering AG (Berlin); Vertex Pharmaceuticals (Cambridge, MA)	Brumby T, McDonald F, Schneider H	8/25/1999	2/22/2001
WO 200112665	A helical cytokine Zalpha48 polypeptide for modulating proliferation, differentiation, migration, and metabolism of responsive cells and for treating rheumatoid arthritis, multiple sclerosis, and diabetes.	ZymoGenetics (Seattle, WA)	Conklin DC	8/18/1999	2/22/2001
WO 200112592	Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, and osteoporosis.	Warner Lambert (Morris Plains, NJ)	Conrad CA, O'Brien PM, Ortwine DF, Picard JA, Sliskovic DR	8/18/1999	2/22/2001
US 6191260	A brain-associated inhibitor of tissue-type plasminogen activator protein useful for the diagnosis and treatment of nervous system-related disorders, such as Alzheimer's disease and multiple sclerosis.	American Natl. Red Cross (Washington, DC); Human Genome Sciences (Rockville, MD)	Coleman TA, Dillon PJ, Hastings GA, Lawrence DA	10/11/1996	2/20/2001
WO 200110893	Interleukin-16 antagonist peptide for treating inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disease, Grave's disease, and multiple sclerosis.	Research Corp. Technologies (Tucson, AZ)	Center DM, Cruikshank WW, Kornfeld H	8/5/1999	2/15/2001
WO 200109110	Novel succinate derivatives useful as cysteine protease inhibitors such as cathepsin S, K, F, L, and B inhibitors; for treating rheumatoid arthritis, multiple sclerosis, and psoriasis.	Boehringer Ingelheim Pharmaceuticals (Ridgefield, CT)	Bekkali Y, Betageri R, Emmanuel M, Hickey E, Liu W, Patel U, Spero DM, Thomson DS, Ward Y, Young ERR	7/30/1999	2/8/2001

Source: Derwent Information, Alexandria, VA. The status of each application is slightly different from country to country. For further details, contact Derwent Information, 1725 Duke Street, Suite 250, Alexandria, VA 22314. Tel: 1 (800) DERWENT ([info@derwent.com](mailto:info@derwent.com)).